MRONJ Staging: Symptoms, Stages, and Treatment

Medication-related osteonecrosis of the jaw (MRONJ) is staged from 0 through 3 based on whether bone is exposed and how far infection or bone destruction has spread, with each stage carrying different symptoms and calling for a different treatment approach. The condition develops as a side effect of drugs that slow bone turnover, particularly bisphosphonates and denosumab, and it can range from vague jaw pain with no visible bone exposure all the way to pathologic fractures and fistulas draining through the skin. Understanding where a case falls in the staging system matters because it shapes whether conservative treatment with antibiotics and mouth rinses will suffice or whether surgery becomes necessary.

What MRONJ Is and Why It Develops

MRONJ occurs when jawbone tissue dies and fails to heal in people who are taking or have recently taken antiresorptive or antiangiogenic medications. The jawbone is uniquely vulnerable because it undergoes more constant remodeling than almost any other bone in the body, driven by the mechanical stresses of chewing and by dental infections that regularly challenge the surrounding bone. When drugs suppress that remodeling process, the jaw loses its ability to repair routine microdamage, and dead bone accumulates without being replaced.

Despite two decades of research, the exact chain of events that triggers MRONJ is still not fully worked out. Several competing theories exist, including suppressed bone turnover, impaired blood supply, altered immune function, and soft-tissue toxicity, but no single hypothesis captures the full picture.¹ What clinicians do know is that the risk is real and that certain drugs and circumstances make it far more likely.

Who Is Most at Risk

The drugs most commonly linked to MRONJ are bisphosphonates (zoledronic acid, alendronate, risedronate) and the monoclonal antibody denosumab. Both are used at lower doses for osteoporosis and at much higher doses for cancer-related bone problems like metastases and hypercalcemia. Cancer patients receiving these medications face a substantially greater risk than osteoporosis patients, partly because of the higher drug doses and partly because cancer itself, along with chemotherapy, suppresses the immune system and disrupts bone remodeling.²

Tooth extraction is the single most important triggering event. A systematic review of cancer patients found that MRONJ developed after roughly a quarter to half of extractions, with individual studies reporting rates between about 11% and 50%.³ Patients on multiple medications appear even more vulnerable, and the mandible (lower jaw) is affected more often than the upper jaw.⁴ Other local risk factors include dental implant placement, periodontal surgery, and ill-fitting dentures that create pressure sores on the gums overlying bone.

The Four Stages and Their Symptoms

The staging system used by most oral and maxillofacial surgery organizations recognizes four categories: a “Stage 0” or at-risk category, plus Stages 1, 2, and 3. The stages are defined primarily by whether dead bone is exposed through the gum tissue and by whether infection or bone destruction has extended beyond the immediate area.

Stage 0

Stage 0 is the most controversial and the hardest to catch. There is no bone visibly poking through the gums, yet the patient has symptoms that suggest something is wrong beneath the surface. These signs are nonspecific and can include dull bone pain, altered sensation or numbness in the jaw, redness or swelling of the overlying gum tissue, and loosening of teeth without an obvious dental cause.⁵ Because none of these symptoms screams “jaw necrosis” on its own, Stage 0 is easy to dismiss as routine dental trouble. Catching it early matters, though, because recognizing Stage 0 before bone becomes exposed may slow progression and improve outcomes.⁶

Stage 1

At Stage 1, dead bone is now visible in the mouth or can be felt by probing through a small opening in the gums. The key distinction from later stages is that there is no active infection: no pus, no significant redness or swelling beyond the immediate area, and the patient may actually have little or no pain. Some people are surprised to learn that exposed dead bone can exist in the mouth without hurting much, but that is typical of Stage 1.

Stage 2

Stage 2 adds infection to the picture. The exposed or prob-able necrotic bone is now accompanied by signs like pain, obvious redness and swelling of the surrounding soft tissue, and sometimes purulent drainage. This is the stage where most patients seek care, because infection drives symptoms that are hard to ignore. A case series treating Stage 2 patients found that a combination of antibiotics, chlorhexidine rinses, and minimally invasive surgical removal of dead bone resulted in complete healing within 12 months for all patients treated.⁷

Stage 3

Stage 3 represents the most advanced disease. The necrotic bone extends well beyond the tooth-bearing area, reaching structures like the lower border of the mandible, the floor of the maxillary sinus, or the cheekbone. At this stage you may see pathologic fractures where weakened bone breaks on its own, fistulas that drain through the skin of the face or connect the mouth to the nasal cavity, and extensive bone destruction visible on imaging.⁸ Stage 3 almost always requires surgical intervention, sometimes including removal of large segments of jawbone.

How MRONJ Is Diagnosed

Diagnosis starts with history and examination. If you are taking an antiresorptive or antiangiogenic drug and you have exposed bone in the jaw (or symptoms consistent with Stage 0), and you have not had radiation therapy to the head or neck, the clinical picture usually points toward MRONJ. The radiation-therapy question is important because osteoradionecrosis looks similar but arises from a different cause.

Imaging helps confirm the extent of disease and distinguish MRONJ from other jaw conditions. Standard panoramic X-rays can show bone changes, but three-dimensional imaging with cone-beam CT (CBCT) is more revealing. CBCT picks up features that are more specific to MRONJ, including a characteristic “bone-within-bone” appearance, new bone forming along the outer surface of the jaw (periosteal reaction), and perforations in the cortical bone that tend to occur on the cheek side.⁹ CBCT also outperforms standard panoramic imaging at detecting periosteal new bone formation and cortical erosion.¹⁰

CBCT imaging also helps separate MRONJ from conditions that mimic it. Compared to ordinary osteomyelitis, MRONJ tends to show more sclerotic (dense, hardened) bone. Compared to osteoradionecrosis, MRONJ shows more periosteal new bone formation. These patterns are not always clear-cut on a regular X-ray, but CBCT identifies more distinguishing features between these conditions.¹¹

Conservative Treatment

For Stage 0 and Stage 1 disease, and sometimes for Stage 2 when surgery is not an option, the first-line approach is medical management. The core regimen involves systemic antibiotics, typically amoxicillin or clindamycin for those allergic to penicillin, sometimes with the addition of metronidazole when a single antibiotic does not control the infection. This is paired with topical antiseptic care: chlorhexidine mouthwash and chlorhexidine gel applied directly to any exposed bone.¹²

This conservative approach can be maintained over many months. A retrospective study following patients on nonsurgical therapy for a year reported improvement in signs and symptoms across the study group, suggesting that antibiotics and antiseptics alone are a reasonable option for patients who cannot undergo surgery.¹³ Hyperbaric oxygen therapy has also been explored as an add-on, with case reports describing successful outcomes and improved quality of life, though the evidence base remains small.¹⁴

When Surgery Becomes Necessary

Surgery is typically reserved for Stage 2 cases that do not respond to conservative treatment and for most Stage 3 cases. The type of surgery depends on how much bone is affected. A study of over 200 patients undergoing surgical treatment for MRONJ in the mandible found that the most common procedure was marginal mandibulectomy, where a strip of bone is removed along the edge of the jaw. Other procedures included removal of separated dead bone (sequestrectomy) and, in the most severe cases, segmental mandibulectomy, where a full-thickness section of the jawbone is taken out.¹⁵ For Stage 3 disease, conservative surgical approaches that combine sequestrectomy with debridement of inflamed soft tissue and bone curettage are also used, particularly when the goal is to preserve as much jawbone as possible.¹⁶

A growing area of interest is the use of platelet-rich fibrin (PRF), a blood concentrate made from the patient’s own blood, placed into the surgical site after extraction or debridement. One prospective study found that PRF applied to extraction sockets in at-risk patients helped normal healing in about 96% of cases, compared to only about 64% without PRF.¹⁷ However, the same study found that PRF was less impressive when applied after debridement of already-established MRONJ lesions, where the difference was not statistically significant. A separate retrospective study using leukocyte-platelet rich fibrin reported that all cases in the PRF group healed, while more than half of non-PRF cases did not.¹⁸ The evidence is still accumulating, but PRF appears most useful as a preventive measure in extraction sockets rather than as a rescue for advanced disease.

Teriparatide as an Emerging Treatment

One of the more promising developments in MRONJ management is teriparatide, a synthetic form of parathyroid hormone that stimulates new bone growth instead of simply preventing bone loss. The logic is straightforward: if MRONJ is fundamentally a failure of bone remodeling, a drug that kickstarts bone formation might help the jaw heal itself.

A randomized, placebo-controlled trial found that teriparatide led to resolution of MRONJ lesions in about 45% of cases by 52 weeks, compared to about 33% in the placebo group, and it also reduced the size of bony defects.¹⁹ Other research suggests teriparatide may reduce the need for surgical intervention altogether and speed recovery by significantly affecting bone metabolism.²⁰ Reviews of the available evidence describe teriparatide as the most promising adjunctive treatment for MRONJ, though they emphasize that larger, well-controlled trials are still needed.²¹

One important caveat: teriparatide is not suitable for everyone. It is generally contraindicated in patients with active bone metastases or certain other cancers, which means that a large portion of the MRONJ population, the cancer patients on high-dose bisphosphonates, may not be candidates for it.

The Drug Holiday Debate

For years, many dentists and oral surgeons have recommended that patients stop their bisphosphonate or denosumab before dental procedures like tooth extraction, with the idea that a “drug holiday” of a few weeks to months would lower the risk of MRONJ. This practice made intuitive sense but has not held up well under scrutiny.

A systematic review and meta-analysis pooling data from multiple studies found no significant difference in MRONJ rates between patients who took a drug holiday and those who did not before tooth extraction.²² Another study looking specifically at osteoporosis patients found that drug holidays of 90, 120, or 180 days showed no improvement in treatment outcomes and did not promote separation of dead bone. The authors concluded that drug holidays for MRONJ treatment are unnecessary and that surgical therapy should proceed without delay.²³ A broader systematic review examining both bisphosphonate and denosumab users reached the same conclusion: there is no evidence supporting drug holidays, though the authors acknowledged that the small and varied patient populations make definitive high-level evidence almost impossible to obtain.²⁴

The practical takeaway is that stopping your bone-protecting medication before a dental procedure likely does not reduce your jaw risk and may expose you to the fracture risk those medications were prescribed to prevent. Decisions about drug holidays should be made jointly between your oncologist or prescribing physician and your dental team, based on your individual situation rather than a blanket protocol.

Prevention and Dental Care Before Starting Treatment

The most effective strategy for reducing MRONJ risk is getting your dental health in order before starting antiresorptive therapy. This means treating active infections, extracting teeth that are likely to need extraction later, and establishing a stable oral-health baseline.²⁵ Once therapy begins, regular dental checkups and good daily oral hygiene become essential for catching problems early before they escalate to the point where invasive treatment is needed.

The reality is that these preventive measures are dramatically underused. A study of cancer patients on antiresorptive therapy found that preventive measures were used in only about 5% of cases, with regular dental checkups occurring in just over 3% and oral hygiene education in under 2%.²⁶ That gap between what is recommended and what actually happens represents a major missed opportunity. If you or someone you know is about to begin bisphosphonate or denosumab treatment, scheduling a thorough dental evaluation beforehand is one of the simplest and most impactful things you can do.

How MRONJ Affects Quality of Life

MRONJ does more than damage bone. It disrupts daily life in ways that standardized questionnaires have now documented. A case-control study found that patients with MRONJ scored significantly worse than matched controls on measures of oral-health-related quality of life, with particular impact on physical pain, functional limitations like difficulty chewing or speaking, and social interactions. Beyond the mouth, MRONJ patients also reported significantly worse scores on broader health measures including physical functioning, energy levels, and general health perception. Anxiety and depression scores were both significantly higher in the MRONJ group.²⁷

The good news is that quality of life tends to improve with treatment. A prospective study tracking patients over time found significant improvement in oral-health quality-of-life scores after treatment, with gains appearing relatively early and then holding steady at later follow-up.²⁸ However, even after surgery, MRONJ leaves a lasting mark. Compared to population norms, MRONJ patients continue to show reduced quality of life, especially in role functioning and social activities. Certain factors predicted worse long-term outcomes, including female sex, breast cancer as the underlying disease, smoking, wearing dentures, and having undergone multiple MRONJ surgeries.²⁹

Can a Blood Test Predict Your Risk?

For years, some clinicians have used a blood test measuring serum C-terminal telopeptide (CTX), a marker of bone breakdown, to gauge whether a patient on bisphosphonates is safe to undergo dental surgery. The idea was that a CTX level below a certain threshold (often cited as 150 pg/mL) would flag patients at higher risk. That particular threshold has not held up. One retrospective study found no significant difference in complication rates above versus below 150 pg/mL and concluded that CTX by itself is not reliable as a predictive measure.³⁰

More recent work has taken a different approach, asking not “what level signals danger” but “what level signals safety.” A systematic review and meta-analysis of osteoporosis patients on oral bisphosphonates estimated that when CTX levels exceed roughly 260 pg/mL, the risk of MRONJ is very low. In the pooled individual patient data, only two osteoporosis patients who developed MRONJ had CTX above 200 pg/mL, and none had levels above 300.³¹ CTX remains the most studied biomarker for MRONJ risk, though researchers have investigated many others, including bone alkaline phosphatase, osteocalcin, vitamin D levels, and inflammatory markers like C-reactive protein.³² None has yet proven reliable enough to serve as a standalone screening tool, but CTX framed as a safety biomarker rather than a danger biomarker is a shift worth watching.

MRONJ in Children and Young Patients

MRONJ is overwhelmingly a disease of adults, particularly older adults being treated for osteoporosis or cancer-related bone problems. But bisphosphonates are also used in children, most commonly for conditions like osteogenesis imperfecta, and denosumab is occasionally used for giant-cell tumors of bone in younger patients. The question of whether these children face a meaningful MRONJ risk has only recently been examined systematically.

A systematic review found that nearly 90% of the included studies reported no cases of MRONJ or impaired jaw healing in children and young patients, even when dental procedures were performed. The handful of reported cases included a child who developed Stage 2 MRONJ after a sports-related tooth fracture required extraction while on denosumab, and a case linked to exploratory jaw surgery.³³ Risk factors in this younger population mirror those in adults: long-term bisphosphonate use and poor oral hygiene stand out, and management follows the same general framework of conservative treatment first with surgery reserved for more advanced cases.³⁴ Overall, the condition appears rare in this age group, but the evidence base is thin enough that vigilance during dental care is still warranted.